2B57

ICD-11 MMS 2026-01

Kaposi sarcoma, primary site

Description

A malignant neoplasm characterised by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).

Coding note from above levels

For use of this category, reference should be made to the mortality coding rules and guidelines in the Reference Guide.

Exclusions from above levels

  • 2A01.1 – Mesenchymal tumour of meninges
  • 2A02.1 – Tumours of cranial or paraspinal nerves
  • http://id.who.int/icd/entity/879154182 – Neoplasms of central nervous system or related structures
Show allHide
  • http://id.who.int/icd/entity/944754984 – Neoplasms of haematopoietic or lymphoid tissues

Child codes

  • 2B57.0 – Kaposi sarcoma of lung
  • 2B57.1 – Kaposi sarcoma of skin
  • 2B57.2 – Kaposi sarcoma of gastrointestinal sites
  • 2B57.Y – Kaposi sarcoma of other specified primary sites
  • 2B57.Z – Kaposi sarcoma of unspecified primary site

Sibling codes

  • 2B50 – Chondrosarcoma, primary site
  • 2B51 – Osteosarcoma, primary site
  • 2B52 – Ewing sarcoma, primary site
  • 2B53 – Fibroblastic or myofibroblastic tumour, primary site
  • 2B54 – Undifferentiated pleomorphic sarcoma, primary site
  • 2B55 – Rhabdomyosarcoma, primary site
  • 2B56 – Angiosarcoma, primary site
  • 2B58 – Leiomyosarcoma, primary site
  • 2B59 – Liposarcoma, primary site
  • 2B5A – Synovial sarcoma, primary site
  • 2B5B – Gastrointestinal stromal tumour, primary site
  • 2B5C – Endometrial stromal sarcoma, primary site
  • 2B5D – Malignant mixed epithelial mesenchymal tumour, primary site
  • 2B5E – Malignant nerve sheath tumour of peripheral nerves or autonomic nervous system, primary site
  • 2B5F – Sarcoma, not elsewhere classified, primary site
  • 2B5G – Myosarcoma of uterus, part not specified
  • 2B5H – Well differentiated lipomatous tumour, primary site
  • 2B5J – Malignant miscellaneous tumours of bone or articular cartilage of other or unspecified sites
  • 2B5K – Unspecified malignant soft tissue tumours or sarcomas of bone or articular cartilage of other or unspecified sites
  • 2B5Y – Other specified malignant mesenchymal neoplasms
  • 2B5Z – Malignant mesenchymal neoplasm of unspecified type

Foundation entity

Kaposi sarcoma, primary site – http://id.who.int/icd/entity/2131977134

Allowed postcoordination axes

Part of: 02: Neoplasms